- Topic
51k Popularity
12k Popularity
8k Popularity
34k Popularity
10k Popularity
- Pin
- 🎉【Gate Singapore Flagship Event · Square Fun Quiz Challenge Day 1】
#TOKEN2049# is just around the corner, and Gate is bringing the heat to Singapore!
Token of Love Music Festival, Gate x Oracle Red Bull Racing Reception, and the F1 Race Viewing are all set to roll out!
Join Square Fun Quiz Challenge now, test how much you know about the events and share $100 BTC in rewards!
To join: Comment your answers (format: 1B 2A 3B 4C)
🎁 Rewards: 3 lucky winners each day → $10 BTC each
👑 Bonus: Answer all questions correctly for 3 days → Extra $10 BTC for Super Quiz King!
📖 Day 1 · Quiz (Single Choic - 💥 Gate Square Event: #SOMI Creative Contest# 💥
Post original content related to SOMI or CandyDrop #76 on Gate Square for a chance to share 180 SOMI rewards!
CandyDrop 76: CandyDrop x Somnia (SOMI)👉 https://www.gate.com/announcements/article/46912
📅 Event Period: Sep 8, 2025 – Sep 15, 2025
📌 How to Participate:
Post original content related to SOMI or the CandyDrop event
Minimum 80 words
Add hashtag: #SOMI Creative Contest#
Include CandyDrop participation screenshot
🏆 Rewards:
🥇 1st Prize (1 winner): 60 SOMI
🥈 2nd Prize (3 winners): 30 SOMI each
🥉 3rd Prize (6 winners): 10 SOMI each
(T - 🚗 #GateSquareCommunityChallenge# Round 1 — Who Will Be The First To The Moon?
Brain challenge, guess and win rewards!
5 lucky users with the correct answers will share $50 GT! 💰
Join:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 16:00, Sep 17 (UTC)
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.